AMISULPRIDE

Details

Stereochemistry	RACEMIC
Molecular Formula	C17H27N3O4S
Molecular Weight	369.479
Optical Activity	( + / - )
Defined Stereocenters	0 / 1
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

CCN1CCCC1CNC(=O)C2=CC(=C(N)C=C2OC)S(=O)(=O)CC

InChI

InChIKey=NTJOBXMMWNYJFB-UHFFFAOYSA-N

InChI=1S/C17H27N3O4S/c1-4-20-8-6-7-12(20)11-19-17(21)13-9-16(25(22,23)5-2)14(18)10-15(13)24-3/h9-10,12H,4-8,11,18H2,1-3H3,(H,19,21)

HIDE SMILES / InChI

Molecular Formula	C17H27N3O4S
Molecular Weight	369.479
Charge	0
Count

Stereochemistry	RACEMIC
Additional Stereochemistry	No
Defined Stereocenters	0 / 1
E/Z Centers	0
Optical Activity	( + / - )

Description
Sources: http://www.sanofi.com.au/products/aus_pi_solian.pdf
Curator's Comment: Description was created based on several sources, including https://www.ncbi.nlm.nih.gov/pubmed/8996185 | https://www.ncbi.nlm.nih.gov/pubmed/19337725 | https://www.ncbi.nlm.nih.gov/pubmed/11735643

Amisulpride, a benzamide derivative, shows a unique therapeutic profile being atypical antipsychotic. At low doses, it enhances dopaminergic neurotransmission by preferentially blocking presynaptic dopamine D2/D3 autoreceptors. At higher doses, amisupride antagonises postsynaptic dopamine D2 and D3 receptors, preferentially in the limbic system rather than the striatum, thereby reducing dopaminergic transmission. In addition its antagonism at serotonin 5-HT7 receptors likely underlies the antidepressant actions. Amisulpride is approved for clinical use in treating schizophrenia in a number of European countries and also for treating dysthymia, a mild form of depression, in Italy.

CNS Activity

Originator

Approval Year

Targets

Primary Target	Pharmacology	Potency
C-C chemokine receptor type 2 19 Target ID: P41597 Gene ID: 729230.0 Gene Symbol: CCR2 Target Organism: Homo sapiens (Human) Sources: https://www.ncbi.nlm.nih.gov/pubmed/10770925	Antagonist 2849	360.0 nM [IC50]
Alpha-1A adrenergic receptor 22 Target ID: P35348\|\|\|B0ZBD9\|\|\|Q6RUJ8 Gene ID: 148.0 Gene Symbol: ADRA1A Target Organism: Homo sapiens (Human) Sources: https://www.ncbi.nlm.nih.gov/pubmed/10770925	Binding Agent 1076	130.0 nM [IC50]
Alpha-1D adrenergic receptor 9 Target ID: P25100 Gene ID: 146.0 Gene Symbol: ADRA1D Target Organism: Homo sapiens (Human) Sources: https://www.ncbi.nlm.nih.gov/pubmed/10770925	Binding Agent 1076	320.0 nM [IC50]
Serotonin 1a (5-HT1a) receptor 177 Target ID: CHEMBL273 Sources: https://www.ncbi.nlm.nih.gov/pubmed/10770925	Binding Agent 1076	470.0 nM [IC50]
Dopamine D2 receptor 311 Target ID: CHEMBL217 Sources: https://www.ncbi.nlm.nih.gov/pubmed/8996185 \| https://www.ncbi.nlm.nih.gov/pubmed/19337725	Antagonist 2849	2.8 nM [Ki]
Dopamine D3 receptor 97 Target ID: CHEMBL234 Sources: https://www.ncbi.nlm.nih.gov/pubmed/8996185 \| https://www.ncbi.nlm.nih.gov/pubmed/19337725	Antagonist 2849	3.2 nM [Ki]
Serotonin 7 (5-HT7) receptor 30 Target ID: CHEMBL3155 Sources: https://www.ncbi.nlm.nih.gov/pubmed/19337725	Antagonist 2849	11.5 nM [Ki]
Serotonin 2b (5-HT2b) receptor 60 Target ID: CHEMBL1833 Sources: https://www.ncbi.nlm.nih.gov/pubmed/19337725	Antagonist 2849	13.0 nM [Ki]

Conditions

Condition	Modality	Targets	Highest Phase	Product
Schizophrenia 305 Sources: http://www.sanofi.com.au/products/aus_pi_solian.pdf	Primary		Approved 8583	SOLIAN Approved Use Amisulpride is indicated for the treatment of acute and chronic schizophrenic disorders, in which positive symptoms (such as delusions, hallucinations, thought disorders) and/or negative symptoms (such as blunted affect, emotional and social withdrawal) are prominent, including patients characterised by predominant negative symptoms.

C_max

Value	Dose	Co-administered	Analyte	Population
586.3 ng/mL EXPERIMENT https://www.ncbi.nlm.nih.gov/pubmed/28793958	200 mg single, oral dose: 200 mg route of administration: Oral experiment type: SINGLE co-administered:		AMISULPRIDE plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED

AUC

Value	Dose	Co-administered	Analyte	Population
5043.2 ng × h/mL EXPERIMENT https://www.ncbi.nlm.nih.gov/pubmed/28793958	200 mg single, oral dose: 200 mg route of administration: Oral experiment type: SINGLE co-administered:		AMISULPRIDE plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED

T_1/2

Value	Dose	Co-administered	Analyte	Population
11.7 h REVIEW https://www.ncbi.nlm.nih.gov/pubmed/12404702	50 mg single, oral dose: 50 mg route of administration: Oral experiment type: SINGLE co-administered:		AMISULPRIDE plasma	Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN

Doses

Dose	Population	Adverse events
6 g single, oral Overdose Dose: 6 g Route: oral Route: single Dose: 6 g Sources: https://pubmed.ncbi.nlm.nih.gov/20531221	unhealthy, 29 years (range: 23-40 years) Health Status: unhealthy Age Group: 29 years (range: 23-40 years) Sex: M+F Sources: https://pubmed.ncbi.nlm.nih.gov/20531221	Other AEs: QT interval prolonged, Tachycardia... Other AEs: QT interval prolonged (64%) Tachycardia (23%) Sources: https://pubmed.ncbi.nlm.nih.gov/20531221
6 g single, oral Overdose Dose: 6 g Route: oral Route: single Dose: 6 g Sources: https://pubmed.ncbi.nlm.nih.gov/20531221	unhealthy, 29 years (range: 23-40 years) Health Status: unhealthy Age Group: 29 years (range: 23-40 years) Sex: M+F Sources: https://pubmed.ncbi.nlm.nih.gov/20531221	Other AEs: Bradycardia, Dystonic reaction... Other AEs: Bradycardia (24%) Dystonic reaction (2 patients) Sources: https://pubmed.ncbi.nlm.nih.gov/20531221
80 g single, oral Overdose Dose: 80 g Route: oral Route: single Dose: 80 g Sources: https://pubmed.ncbi.nlm.nih.gov/20531221	unhealthy, 29 years (range: 23-40 years) Health Status: unhealthy Age Group: 29 years (range: 23-40 years) Sex: M+F Sources: https://pubmed.ncbi.nlm.nih.gov/20531221	Other AEs: Torsades de pointes... Other AEs: Torsades de pointes (7%) Sources: https://pubmed.ncbi.nlm.nih.gov/20531221
20 mg single, intravenous Highest studied dose Dose: 20 mg Route: intravenous Route: single Dose: 20 mg Sources: https://pubmed.ncbi.nlm.nih.gov/28801850	unhealthy Health Status: unhealthy Sources: https://pubmed.ncbi.nlm.nih.gov/28801850	Sources: https://pubmed.ncbi.nlm.nih.gov/28801850
200 mg single, oral Highest studied dose Dose: 200 mg Route: oral Route: single Dose: 200 mg Sources: https://pubmed.ncbi.nlm.nih.gov/28793958	healthy Health Status: healthy Sex: M+F Sources: https://pubmed.ncbi.nlm.nih.gov/28793958	Sources: https://pubmed.ncbi.nlm.nih.gov/28793958
1200 mg single, oral Overdose Dose: 1200 mg Route: oral Route: single Dose: 1200 mg Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/209510s000lbl.pdf	unhealthy Health Status: unhealthy Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/209510s000lbl.pdf	Other AEs: Extrapyramidal disorder... Other AEs: Extrapyramidal disorder Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/209510s000lbl.pdf
3000 mg single, oral Overdose Dose: 3000 mg Route: oral Route: single Dose: 3000 mg Sources: https://pubmed.ncbi.nlm.nih.gov/7779461	unhealthy Health Status: unhealthy Sources: https://pubmed.ncbi.nlm.nih.gov/7779461	Other AEs: Hyperthermia, Mydriasis... Other AEs: Hyperthermia (1 patient) Mydriasis (1 patient) Coma (1 patient) Seizures (1 patient) Sources: https://pubmed.ncbi.nlm.nih.gov/7779461

AEs

AE	Significance	Dose	Population
Tachycardia	23%	6 g single, oral Overdose Dose: 6 g Route: oral Route: single Dose: 6 g Sources: https://pubmed.ncbi.nlm.nih.gov/20531221	unhealthy, 29 years (range: 23-40 years) Health Status: unhealthy Age Group: 29 years (range: 23-40 years) Sex: M+F Sources: https://pubmed.ncbi.nlm.nih.gov/20531221
QT interval prolonged	64%	6 g single, oral Overdose Dose: 6 g Route: oral Route: single Dose: 6 g Sources: https://pubmed.ncbi.nlm.nih.gov/20531221	unhealthy, 29 years (range: 23-40 years) Health Status: unhealthy Age Group: 29 years (range: 23-40 years) Sex: M+F Sources: https://pubmed.ncbi.nlm.nih.gov/20531221
Dystonic reaction	2 patients	6 g single, oral Overdose Dose: 6 g Route: oral Route: single Dose: 6 g Sources: https://pubmed.ncbi.nlm.nih.gov/20531221	unhealthy, 29 years (range: 23-40 years) Health Status: unhealthy Age Group: 29 years (range: 23-40 years) Sex: M+F Sources: https://pubmed.ncbi.nlm.nih.gov/20531221
Bradycardia	24%	6 g single, oral Overdose Dose: 6 g Route: oral Route: single Dose: 6 g Sources: https://pubmed.ncbi.nlm.nih.gov/20531221	unhealthy, 29 years (range: 23-40 years) Health Status: unhealthy Age Group: 29 years (range: 23-40 years) Sex: M+F Sources: https://pubmed.ncbi.nlm.nih.gov/20531221
Torsades de pointes	7%	80 g single, oral Overdose Dose: 80 g Route: oral Route: single Dose: 80 g Sources: https://pubmed.ncbi.nlm.nih.gov/20531221	unhealthy, 29 years (range: 23-40 years) Health Status: unhealthy Age Group: 29 years (range: 23-40 years) Sex: M+F Sources: https://pubmed.ncbi.nlm.nih.gov/20531221
Extrapyramidal disorder		1200 mg single, oral Overdose Dose: 1200 mg Route: oral Route: single Dose: 1200 mg Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/209510s000lbl.pdf	unhealthy Health Status: unhealthy Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/209510s000lbl.pdf
Coma	1 patient	3000 mg single, oral Overdose Dose: 3000 mg Route: oral Route: single Dose: 3000 mg Sources: https://pubmed.ncbi.nlm.nih.gov/7779461	unhealthy Health Status: unhealthy Sources: https://pubmed.ncbi.nlm.nih.gov/7779461
Hyperthermia	1 patient	3000 mg single, oral Overdose Dose: 3000 mg Route: oral Route: single Dose: 3000 mg Sources: https://pubmed.ncbi.nlm.nih.gov/7779461	unhealthy Health Status: unhealthy Sources: https://pubmed.ncbi.nlm.nih.gov/7779461
Mydriasis	1 patient	3000 mg single, oral Overdose Dose: 3000 mg Route: oral Route: single Dose: 3000 mg Sources: https://pubmed.ncbi.nlm.nih.gov/7779461	unhealthy Health Status: unhealthy Sources: https://pubmed.ncbi.nlm.nih.gov/7779461
Seizures	1 patient	3000 mg single, oral Overdose Dose: 3000 mg Route: oral Route: single Dose: 3000 mg Sources: https://pubmed.ncbi.nlm.nih.gov/7779461	unhealthy Health Status: unhealthy Sources: https://pubmed.ncbi.nlm.nih.gov/7779461

Overview

CYP3A4	CYP2C9	CYP2D6	hERG
substrate 1946 inhibitor 2252 inducer 1087	substrate 1193 inhibitor 2438	substrate 1388 inhibitor 2507	inhibitor 2217

OverviewOther

Other Inhibitor	Other Substrate	Other Inducer
CYP2B6 926 CYP2C8 1057 CYP2C19 2057 OCT1 620 MATE2 267 OCT2 779 OAT3 747 P-gp 1741 BCRP 910 OATP1B3 961 OAT1 725 OATP1B1 1079 MATE1 415 CYP1A2 2153	CYP1A2 1197 CYP2A6 626 CYP2B6 776 CYP2C8 810 CYP2C19 1119 CYP2E1 729 P-gp 2052 BCRP 697 MATE2 98 OCT1 393 OATP1B1 503 OATP1B3 435 OAT1 395 OAT3 391 OCT2 434	CYP1A2 832 CYP2B6 669

Drug as perpetrator

Target	Modality	Activity
CYP2D6 2546	inhibitor 4027 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2020/209510Orig1s000MultidisciplineR.pdf#page=99 Page: 99.0	no [IC50 46.1 uM]
BCRP 985	inhibitor 4027 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2020/209510Orig1s000MultidisciplineR.pdf#page=180 Page: 180.0	no [IC50 >100 uM]
P-gp 1932	inhibitor 4027 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2020/209510Orig1s000MultidisciplineR.pdf#page=180 Page: 180.0	no [IC50 >100 uM]
CYP1A2 2333	inducer 1966 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2020/209510Orig1s000MultidisciplineR.pdf#page=179 Page: 179.0	no
CYP1A2 2333	inhibitor 4027 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2020/209510Orig1s000MultidisciplineR.pdf#page=99 Page: 99.0	no
CYP2B6 1160	inducer 1966 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2020/209510Orig1s000MultidisciplineR.pdf#page=179 Page: 179.0	no
CYP2B6 1160	inhibitor 4027 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2020/209510Orig1s000MultidisciplineR.pdf#page=99 Page: 99.0	no
CYP2C19 2141	inhibitor 4027 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2020/209510Orig1s000MultidisciplineR.pdf#page=99 Page: 99.0	no
CYP2C8 1117	inhibitor 4027 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2020/209510Orig1s000MultidisciplineR.pdf#page=99 Page: 99.0	no
CYP2C9 2497	inhibitor 4027 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2020/209510Orig1s000MultidisciplineR.pdf#page=99 Page: 99.0	no
CYP3A4 2633	inducer 1966 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2020/209510Orig1s000MultidisciplineR.pdf#page=179 Page: 179.0	no
CYP3A4 2633	inhibitor 4027 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2020/209510Orig1s000MultidisciplineR.pdf#page=99 Page: 99.0	no
OAT1 730	inhibitor 4027 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2020/209510Orig1s000MultidisciplineR.pdf#page=180 Page: 180.0	no
OATP1B1 1095	inhibitor 4027 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2020/209510Orig1s000MultidisciplineR.pdf#page=180 Page: 180.0	no
OATP1B3 970	inhibitor 4027 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2020/209510Orig1s000MultidisciplineR.pdf#page=180 Page: 180.0	no
OAT3 749	inhibitor 4027 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2020/209510Orig1s000MultidisciplineR.pdf#page=180 Page: 180.0	weak [Inhibition 100 uM]
OCT2 782	inhibitor 4027 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2020/209510Orig1s000MultidisciplineR.pdf#page=180 Page: 180.0	weak [Inhibition 100 uM]
MATE2 267	inhibitor 4027 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2020/209510Orig1s000MultidisciplineR.pdf#page=180 Page: 180.0	yes [IC50 10.1 uM]
OCT1 656	inhibitor 4027 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2020/209510Orig1s000MultidisciplineR.pdf#page=180 Page: 180.0	yes [IC50 16.1 uM]
MATE1 416	inhibitor 4027 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2020/209510Orig1s000MultidisciplineR.pdf#page=87 Page: 87.0	yes

Drug as victim

Target	Modality	Activity
CYP1A2 1197	substrate 4014 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2020/209510Orig1s000MultidisciplineR.pdf#page=99 Page: 99.0	no
CYP2A6 626	substrate 4014 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2020/209510Orig1s000MultidisciplineR.pdf#page=99 Page: 99.0	no
CYP2B6 776	substrate 4014 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2020/209510Orig1s000MultidisciplineR.pdf#page=99 Page: 99.0	no
CYP2C19 1119	substrate 4014 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2020/209510Orig1s000MultidisciplineR.pdf#page=99 Page: 99.0	no
CYP2C8 810	substrate 4014 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2020/209510Orig1s000MultidisciplineR.pdf#page=99 Page: 99.0	no
CYP2C9 1193	substrate 4014 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2020/209510Orig1s000MultidisciplineR.pdf#page=99 Page: 99.0	no
CYP2D6 1388	substrate 4014 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2020/209510Orig1s000MultidisciplineR.pdf#page=99 Page: 99.0	no
CYP2E1 729	substrate 4014 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2020/209510Orig1s000MultidisciplineR.pdf#page=99 Page: 99.0	no
CYP3A4 1946	substrate 4014 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2020/209510Orig1s000MultidisciplineR.pdf#page=99 Page: 99.0	no
OAT1 395	substrate 4014 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2020/209510Orig1s000MultidisciplineR.pdf#page=180 Page: 180.0	no
OAT3 391	substrate 4014 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2020/209510Orig1s000MultidisciplineR.pdf#page=180 Page: 180.0	no
OATP1B1 503	substrate 4014 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2020/209510Orig1s000MultidisciplineR.pdf#page=180 Page: 180.0	no
OATP1B3 435	substrate 4014 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2020/209510Orig1s000MultidisciplineR.pdf#page=180 Page: 180.0	no
OCT2 434	substrate 4014 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2020/209510Orig1s000MultidisciplineR.pdf#page=180 Page: 180.0	no
OCT1 393	substrate 4014 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2020/209510Orig1s000MultidisciplineR.pdf#page=179 Page: 179.0	weak
BCRP 697	substrate 4014 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2020/209510Orig1s000MultidisciplineR.pdf#page=179 Page: 179.0	yes
MATE2 98	substrate 4014 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2020/209510Orig1s000MultidisciplineR.pdf#page=179 Page: 179.0	yes
P-gp 2052	substrate 4014 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2020/209510Orig1s000MultidisciplineR.pdf#page=179 Page: 179.0	yes

Tox targets

Target	Modality	Activity	Metabolite	Clinical evidence
hERG 2263	inhibitor 2237 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2020/209510Orig1s000MultidisciplineR.pdf#page=59 Page: 59.0

Sourcing

Vendor/Aggregator	ID	URL
ChEBI	CHEBI:64045	https://www.ebi.ac.uk/chebi/searchId.do?chebiId=CHEBI:64045
ChemicalBook	CB7312326	https://www.chemicalbook.com/ChemicalProductProperty_EN_CB7312326
eMolecules	1985473	https://www.emolecules.com/cgi-bin/more?vid=1985473
MolPort	MolPort-003-983-463	https://www.molport.com/shop/molecule-link/MolPort-003-983-463
Selleck Chemicals	Amisulpride	http://www.selleckchem.com/products/Amisulpride.html

PubMed

Title	Date	PubMed
Prolactinemia is uncoupled from central D2/D3 dopamine receptor occupancy in amisulpride treated patients.	2004-09	14997280
Evidence-based pharmacotherapy of schizophrenia.	2004-06	15043765
Successful treatment of Tourette's disorder with amisulpride.	2004-05	15010520
Amisulpride is an "atypical" antipsychotic associated with low weight gain.	2004-04	14647963
Dopaminergic receptors in rat dura mater: pharmacological characteristics.	2004-03	15008964
Dosage finding and outcome in the treatment of schizophrenic inpatients with amisulpride. Results of a drug utilization observation study.	2004-03	14994321
Lower risk for tardive dyskinesia associated with second-generation antipsychotics: a systematic review of 1-year studies.	2004-03	14992963
How do we choose between atypical antipsychotics? The advantages of amisulpride.	2004-03	14972081
Amisulpride a selective dopamine antagonist and atypical antipsychotic: results of a meta-analysis of randomized controlled trials.	2004-03	14972080
Combination of amisulpride and olanzapine in treatment-resistant schizophrenic psychoses.	2004-02	14969782
Combination of clozapine and amisulpride in treatment-resistant schizophrenia--case reports and review of the literature.	2004-01	14750045
Characterization of the effects of receptor-selective ligands in rats discriminating the novel antipsychotic quetiapine.	2004-01	14691616
Adverse metabolic effects associated with atypical antipsychotics: literature review and clinical implications.	2004	15025545
Quetiapine. A review of its use in the management of schizophrenia.	2004	14871161
How does the benzamide antipsychotic amisulpride get into the brain?--An in vitro approach comparing amisulpride with clozapine.	2003-11	12865899
The antinociceptive effect of amisulpride in mice is mediated through opioid mechanisms.	2003-10-08	14575800
Metabolic drug interactions with new psychotropic agents.	2003-10	14703714
Amisulpride: limbic specificity and the mechanism of antipsychotic atypicality.	2003-10	14642970
Response of catatonic schizophrenia to amisulpride: a case report.	2003-09	14574833
Analysis of eighteen antidepressants, four atypical antipsychotics and active metabolites in serum by liquid chromatography: a simple tool for therapeutic drug monitoring.	2003-08-25	12888196
Is regionally selective D2/D3 dopamine occupancy sufficient for atypical antipsychotic effect? an in vivo quantitative [123I]epidepride SPET study of amisulpride-treated patients.	2003-08	12900302
Rapid high-performance liquid chromatographic measurement of amisulpride in human plasma: application to manage acute intoxication.	2003-06-05	12726848
Lack of effect of amisulpride on the pharmacokinetics and safety of lithium.	2003-06	12890302
A meta-analysis of the efficacy of second-generation antipsychotics.	2003-06	12796218
New generation antipsychotics versus low-potency conventional antipsychotics: a systematic review and meta-analysis.	2003-05-10	12747876
[Plasma prolactin level and incidence of adverse endocrinologic effects during therapy with atypical neuroleptics].	2003-05	14509051
The new and evolving pharmacotherapy of schizophrenia.	2003-03	12683264
Screening, library-assisted identification and validated quantification of fifteen neuroleptics and three of their metabolites in plasma by liquid chromatography/mass spectrometry with atmospheric pressure chemical ionization.	2003-03	12644990
Automated determination of amisulpride by liquid chromatography with column switching and spectrophotometric detection.	2003-02-05	12505788
Which neuroleptic would psychiatrists take for themselves or their relatives?	2003-02	12648897
Respective roles of dopamine D2 and D3 receptors in food-seeking behaviour in rats.	2003-02	12525958
Amisulpride versus risperidone in the treatment of schizophrenic patients: a double-blind pilot study in Taiwan.	2003-01	12684609
[Frontal dysfunctions in Huntington's disease -- neuropsychology and therapy].	2003-01	12524580
Quantification of D2-like dopamine receptors in the human brain with 18F-desmethoxyfallypride.	2003-01	12515884
New generation antipsychotics for first episode schizophrenia.	2003	14584012
Benefits and risks of pharmacotherapy for dysthymia: a systematic appraisal of the evidence.	2003	12495364
Dopaminergic deficit and the role of amisulpride in the treatment of schizophrenia.	2002-12	12685918
Dopaminergic deficit and the role of amisulpride in the treatment of mood disorders.	2002-12	12685917
Liver function tests during treatment with antipsychotic drugs: a case series of 23 patients.	2002-12	12502031
Effects of amisulpride on consummatory negative contrast.	2002-12	12478217
Amisulpride vs. risperidone in chronic schizophrenia: results of a 6-month double-blind study.	2002-12	12464464
Dose-related effects of amisulpride on five dimensions of psychopathology in patients with acute exacerbation of schizophrenia.	2002-12	12454554
Discriminative stimulus properties in rats of the novel antipsychotic quetiapine.	2002-11	12498334
A comparison of paroxetine versus paroxetine plus amisulpride in the treatment of dysthymic disorder: efficacy and psychosocial outcomes.	2002-10-10	12429360
Amisulpride: is there a treatment for negative symptoms in schizophrenia patients?	2002	12693427
A double-blind, randomised comparative trial of amisulpride versus olanzapine in the treatment of schizophrenia: short-term results at two months.	2002	12442883
Switching to amisulpride.	2002	12418609
Amisulpride: progress and outcomes.	2002	12418608
Clinical implications of dopamine research in schizophrenia.	2002	12418605
Pharmacology of human dopamine D3 receptor expressed in a mammalian cell line: comparison with D2 receptor.	1992-04-10	1354163

Patents

Sample Use Guides

In Vivo Use Guide

For acute psychotic episodes, oral doses between 400 mg/d and 800 mg/d are recommended. In individual cases, the daily dose may be increased up to 1200 mg/d. Doses above 1200 mg/d have not been extensively evaluated for safety and therefore should not be used. Doses above 800 mg/d have not been shown to be superior to lower doses and may increase the incidence of adverse events. No specific titration is required when initiating the treatment with amisulpride. Doses should be adjusted according to individual response.

Route of Administration: Oral

In Vitro Use Guide

In NG108-15 cells stably transfected with the human D3 dopamine receptor amisulpride inhibited quinpirole-elicited mitogenesis with an IC50 value of 22 nM

Substance Class	Chemical Created by `admin` on `Wed Apr 02 09:13:21 GMT 2025` Edited by `admin` on `Wed Apr 02 09:13:21 GMT 2025`
Record UNII	8110R61I4U
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

DENIBAN

Preferred Name

English

AMISULPRIDE

Official Name

English

Amisulpride [WHO-DD]

Common Name

English

APD421

Code

English

BARHEMSYS

Brand Name

English

BENZAMIDE, 4-AMINO-N-((1-ETHYL-2-PYRROLIDINYL)METHYL)-5-(ETHYLSULFONYL)-2-METHOXY-

Systematic Name

English

SULAMID

Brand Name

English

DAN-2163

Code

English

AMISULPRIDE [MI]

Common Name

English

APD-421

Code

English

SOLIAN

Brand Name

English

NSC-760085

Code

English

(±)-AMISULPRIDE

Common Name

English

AMISULPRIDE [EP MONOGRAPH]

Common Name

English

SOCIAN

Brand Name

English

AMISULPRIDE [MART.]

Common Name

English

4-AMINO-N-((1-ETHYL-2-PYRROLIDINYL)METHYL)-5-(ETHYLSULFONYL)-O-ANISAMIDE

Common Name

English

AMISULPRIDE [ORANGE BOOK]

Common Name

English

amisulpride [INN]

Common Name

English

AMINOSULTOPRIDE

Common Name

English

Classification Tree Code System Code

NCI_THESAURUS

C66883